The antiseizure effect of resveratrol on pentylenetetrazole-induced seizures during different phases of the estrous cycle in rats
Year: 2026
Type: article
Abstract: This research investigated the effects of resveratrol on seizure suppression in a rat model of catamenial epilepsy, focusing on variations through the estrus cycle. Female Wistar rats were randomly divided into five groups: control (saline), valproic acid (VPA, 75 mg/kg), and resveratrol at doses of 20, 40, and 80 mg/kg. Each group was further divided into four subgroups corresponding to the phases of the estrus cycle (proestrus, estrus, metestrus, and diestrus). Rats received intraperitoneal injections of either saline or pentylenetetrazol (PTZ, 80 mg/kg). Seizure initiation times and durations for myoclonic (ITMS) and tonic-clonic seizures (ITTS) were recorded. Blood samples were collected to assess serum concentrations of MDA, SOD, GPx, TNF-α, and IL-1β. Resveratrol at 80 mg/kg significantly increased both ITMS and ITTS throughout all estrous phases compared to controls (p ˂0.05). Both VPA and resveratrol treatment significantly reduced seizure duration (p ˂0.05). Resveratrol demonstrated a more pronounced antiseizure effect during the metestrus and diestrus phases. Resveratrol decreased MDA levels and increased SOD and GPx activity (p ˂0.05). TNF-α and IL-1β were also reduced following resveratrol administration (p ˂0.05). Overall, resveratrol decreased seizures in PTZ-treated rats, with it being more effective during the luteal phase compared to the follicular phase.
Source: IBRO Neuroscience Reports
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,400
OpenAlex ID: W7223455151